N/A
Manufactured by H2-Pharma LLC
42,593 FDA adverse event reports analyzed
Last updated: 2026-04-14
HYDROXYUREA is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by H2-Pharma LLC. The most commonly reported adverse reactions for HYDROXYUREA include OFF LABEL USE, FATIGUE, SICKLE CELL ANAEMIA WITH CRISIS, DIARRHOEA, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for HYDROXYUREA.
Out of 20,424 classified reports for HYDROXYUREA:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 42,593 FDA FAERS reports that mention HYDROXYUREA. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, FATIGUE, SICKLE CELL ANAEMIA WITH CRISIS, DIARRHOEA, NAUSEA, HEADACHE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list H2-Pharma LLC in connection with HYDROXYUREA. Always verify the specific product and NDC with your pharmacist.